Related Experiment Video
Updated: Mar 10, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Competing Cardiometabolic Pathways of Obesity and Metabolic Dysfunction-associated Steatotic Liver Disease
Masashi Hirooka1, Teruki Miyake2, Ryo Yano2
1Total Medical Support Center, Ehime University Hospital, Toon, Japan.
Background And Aims:
Metabolic dysfunction-associated steatotic liver disease (MASLD) progression is influenced by other metabolic disorders. However, quantitative evidence regarding disease pathway competition remains limited. In the current study, we utilized competing risk survival analysis to determine whether obesity-related MASLD development competes with hypertension and type 2 diabetes pathways.
Methods:
We conducted a 13-year (2007-2020) prospective cohort study involving 16,770 participants without MASLD, hypertension, or type 2 diabetes at baseline. Competing risk regression modeled the first occurrence of each disease during follow-up. Subdistribution hazard ratios (HRs) were estimated adjusting for age, sex, and baseline cardiometabolic parameters, with sensitivity analyses across body mass index (BMI) cutoffs and demographic subgroups.
Results:
Over a median follow-up of 8.3 years, high BMI (≥25 kg/m2) strongly increased MASLD risk (adjusted HR: 4.54; 95% confidence interval [CI]: 4.03-5.11; P < .001). In traditional Cox regression, high BMI increased hypertension risk (HR: 1.12; 95% CI: 1.06-1.19; P < .001). However, in competing risk analysis for MASLD development, an inverse association emerged (subdistribution HR: 0.87; 95% CI: 0.77-0.99; P = .032), suggesting a pathway effect rather than biological protection.
Conclusion:
Individuals with a high BMI who developed MASLD exhibited a lower incidence of subsequent hypertension, suggesting apparent inverse associations that may reflect competing metabolic pathways. These findings suggest that obesity-related metabolic dysfunction may progress along distinct pathways-hepatic vs vascular-thereby supporting phenotype-specific risk stratification.
More Related Videos
Related Concept Videos
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...

